<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bhari VK</submitter><funding>Start-up Research</funding><funding>Science and Engineering Research Board</funding><funding>Manipal University Jaipur</funding><pagination>100844</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7643628</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24</volume><pubmed_abstract>The recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has impacted the world severely. The binding of the SARS-CoV-2 virus to the angiotensin-converting enzyme 2 (ACE2) and its intake by the host cell is a necessary step for infection. ACE2 has garnered widespread therapeutic possibility as it is entry/interactive point for SARS-CoV-2, responsible for coronavirus disease 2019 (COVID-19) pandemic and providing a critical regulator for immune modulation in various disease. Patients with suffering from cancer always being on the verge of being immune compromised therefore gaining knowledge about how SARS-CoV-2 viruses affecting immune cells in human cancers will provides us new opportunities for preventing or treating virus-associated cancers. Despite C</pubmed_abstract><journal>Biochemistry and biophysics reports</journal><pubmed_title>SARS-CoV-2 cell receptor gene ACE2 -mediated immunomodulation in breast cancer subtypes.</pubmed_title><pmcid>PMC7643628</pmcid><funding_grant_id>SRG/2019/001049</funding_grant_id><funding_grant_id>EF/2018-19/QE04-11</funding_grant_id><pubmed_authors>Kumar D</pubmed_authors><pubmed_authors>Bhari VK</pubmed_authors><pubmed_authors>Mishra R</pubmed_authors><pubmed_authors>Kumar S</pubmed_authors></additional><is_claimable>false</is_claimable><name>SARS-CoV-2 cell receptor gene ACE2 -mediated immunomodulation in breast cancer subtypes.</name><description>The recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has impacted the world severely. The binding of the SARS-CoV-2 virus to the angiotensin-converting enzyme 2 (ACE2) and its intake by the host cell is a necessary step for infection. ACE2 has garnered widespread therapeutic possibility as it is entry/interactive point for SARS-CoV-2, responsible for coronavirus disease 2019 (COVID-19) pandemic and providing a critical regulator for immune modulation in various disease. Patients with suffering from cancer always being on the verge of being immune compromised therefore gaining knowledge about how SARS-CoV-2 viruses affecting immune cells in human cancers will provides us new opportunities for preventing or treating virus-associated cancers. Despite C</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Dec</publication><modification>2025-04-04T10:25:28.102Z</modification><creation>2020-11-09T08:47:41Z</creation></dates><accession>S-EPMC7643628</accession><cross_references><pubmed>33178900</pubmed><doi>10.1016/j.bbrep.2020.100844</doi></cross_references></HashMap>